PFA pdf
Awaiting price reaction for this filing.
Nutraplus India Ltd filed its quarterly results for Q3 ended December 31, 2021 on October 14, 2024 — a delay of nearly 3 years. The auditor issued a Qualified Limited Review Report because the company failed to comply with SEBI listing requirements and did not provide necessary financial data in a timely manner. The auditor also included an Emphasis of Matter noting the company lost all its property, plant and equipment under the SARFAESI Act, 2002 after being declared a Non-Performing Asset in FY2019-20, with the asset auction delayed due to COVID-19. For the nine months ended Dec 2021, total income was Rs 70.49 lakh vs Rs 7.19 lakh in the prior year period, and net profit was Rs 67.24 lakh vs a net loss of Rs 48.16 lakh in the prior year period. The year ended March 2021 showed a net loss of Rs 2,366.45 lakh including an exceptional item of Rs 1,780.35 lakh (asset auction loss). The company now has minimal operations with zero revenue from operations reported in Q3 Dec 2021.
The company is in severe distress — declared NPA, lost all operating assets, filed results 3 years late, and received a qualified auditor opinion. Shareholders face extreme risk as the company has effectively ceased its core pharmaceutical manufacturing business. The stock is likely illiquid and speculative.